Cn /En

News Center

——

Company news

Industry news

InnoModels: Characteristics of the PBMC-OncVax tumor vaccine model

Author:

InnoModels

Release time:

2024-03-05

In the field of cancer immunotherapy, tumor vaccines are receiving more and more attention as a novel therapeutic strategy. As an experimental model designed for tumor vaccine development, the PBMC-OncVax tumor vaccine model of InnoModels Biotechnology plays an important role in cancer research with its unique features and advantages. In this paper, we will introduce the features of the PBMC-OncVax tumor vaccine model of InnoModels Biotechnology in detail and discuss its application prospects.
Model features:
1. Highly simulates the tumor environment: The InnoModels Biotechnology PBMC-OncVax model uses the patient's peripheral blood mononuclear cells (PBMC) combined with tumor antigens to construct an experimental system that highly simulates the tumor microenvironment. This model can reflect the interaction between immune cells and tumor cells within the tumor tissue, providing a more realistic experimental platform for the development of tumor vaccines.
2. Individualized treatment strategy: Since the model uses patients' PBMCs, personalized tumor vaccine treatment plans can be formulated for individual differences of patients. Through the screening and processing of patients' PBMC, immune cells with high affinity for tumor cells can be screened out, thus enhancing the efficacy of the tumor vaccine.
3. Real-time monitoring of therapeutic effect: The PBMC-OncVax model can monitor the therapeutic effect of the tumor vaccine in vivo in real time. By monitoring the immune cell activity, cytokine secretion and other indicators in the model, the degree of activation of the tumor vaccine on the immune system and the growth inhibition of tumor cells can be assessed.
4. High safety: Compared with traditional tumor treatments, the tumor vaccine used in the InnoModels PBMC-OncVax model has lower side effects and higher safety. Since the model uses the patient's own PBMC, there is no risk of immune rejection, and the probability of adverse reactions such as allergic reactions is also reduced.

Application Prospects:
As a novel tool for cancer immunotherapy, the PBMC-OncVax tumor vaccine model of InnoModels Biotechnology has a broad application prospect. With the continuous development of the field of cancer immunotherapy, the model will play an important role in the following aspects:
1. Tumor vaccine research and development: By using the Genomics PBMC-OncVax model, the effect and safety of tumor vaccines can be more accurately assessed, providing strong support for the development of new tumor vaccines.
2. Individualized treatment plan: The model can be used to develop individualized tumor vaccine treatment plans based on patients' individual differences, which can improve the treatment effect and reduce the probability of adverse reactions.
3. Real-time monitoring of therapeutic effect: By monitoring the immune cell activity and other indicators in the model, the therapeutic effect of the tumor vaccine in vivo can be monitored in real time, providing more accurate data support for clinical decision-making.
4. Explore new immunotherapy strategies: The PBMC-OncVax model can also be used to explore new immunotherapy strategies, such as combining tumor vaccines with other immunotherapeutic drugs, in order to improve the overall effect of cancer treatment.
In summary, the PBMC-OncVax tumor vaccine model of InnoModels Biotechnology shows great potential and value in the field of cancer immunotherapy with its highly simulated tumor environment, personalized treatment strategies, real-time monitoring of treatment effects and high safety. With the continuous progress of cancer immunotherapy technology and the improvement of experimental methods, the model will play a more important role in promoting the development of cancer immunotherapy.

InnoModels: Advantages of MHC Humanized Mouse Models

InnoModels: Characteristics and Application Prospects of PBMC Mixed Inoculation Models

InnoModels: Advantages of MHC Humanized Mouse Models

InnoModels: Characteristics and Application Prospects of PBMC Mixed Inoculation Models

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL: +86 15711355061
E-mail: xuyl@imodels.tech
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

InnoModels Biotechnology (Beijing) Co., Ltd

SEO

Business License